Skip to main
DRIO

DarioHealth (DRIO) Stock Forecast & Price Target

DarioHealth (DRIO) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

DarioHealth is well-positioned to capitalize on the growing digital therapeutics market as it continues to expand its vertical integration strategy and deliver personalized evidence-based interventions. With strong channel partner traction, improving gross margins, and a target break-even cash flow by 1Q27, the company's focus on enterprise adoption and growth will likely lead to share gains, upward earnings revision, and multiple expansion. However, DarioHealth faces potential risks associated with the HCIT industry, such as government program cuts and price competition.

Bears say

DarioHealth is currently performing well, with a strong B2C revenue of $2.9M in Q1 and a growing pipeline of $127M. However, a challenging digital health demand environment and potential limited investment by DRIO may hinder revenue growth, and their recent dilutive capital raise suggests potential struggles in the near to medium term. Their 2027 revenue and EBITDA estimates have been adjusted slightly, and there is potential for upside if they can cross-sell to legacy Twill customers and control OpEx better.

DarioHealth (DRIO) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DarioHealth and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DarioHealth (DRIO) Forecast

Analysts have given DarioHealth (DRIO) a Buy based on their latest research and market trends.

According to 2 analysts, DarioHealth (DRIO) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DarioHealth (DRIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.